Navigation Links
Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care

WOBURN, Mass., Feb. 22, 2011 /PRNewswire/ -- MedTrust Online (MedTrust) and Avantra Biosciences (Avantra) announced today a novel collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx™ multiplex immunoassay system.

The two companies will provide a global community of over 10,000 cancer care professionals with early access to the latest panels of protein biomarkers implicated in different cancers.  Avantra, based in Woburn, MA, is a leading innovator in protein diagnostics and recently announced the commercialization of the new Q400 Biomarker Workstation and innovative AngioGenQx™ BioChip immunoassay.  The system provides quantitative protein biomarker results for ten analytes in less than an hour, requiring only five minutes for sample preparation.  

As Avantra's scientific development team identifies biomarkers of interest for its QPDx™ system, MedTrust will use its Knowledge Medicine™ platform to engage oncologists in online discussions that will validate the role of different panels in diagnosis, prognosis, and treatment efficacy in cancer care.  The first of several multiplex assays to be evaluated include an upcoming panel developed in the recently announced collaboration between Avantra and TGen Drug Development.  Avantra intends to develop additional panels that may target ovarian, pancreatic, lung, prostate, breast, and colorectal cancers to uncover associations between protein marker levels and patient drug responses that can positively impact clinical decisions.   Currently available for research use only (RUO), Avantra intends to seek regulatory approval for its assay technologies as the clinical utility of the molecular information becomes evident.   In addition to oncology, Avantra is exploring opportunities in other areas such as infectious disease through its upcoming panel for sepsis.

"Avantra is excited to work with MedTrust Online and their clinical experts on this joint collaboration.  Avantra's novel QPDx system is an easy-to-use multiplex protein biomarker technology that will provide MedTrust's user base with rapid, high utility, protein biomarker data.  Avantra is working on several key strategic initiatives to combine proteomic and genomic products and services technologies that will assist professionals in the research, clinical and pharmaceutical fields to make better decisions for drug profiling, patient stratification and disease management.  Our relationship with MedTrust Online is another key component to our strategy for building Avantra and our long term vision," said Brian McKernan, CEO of Avantra Biosciences.

"This partnership will provide cancer doctors with powerful biomarker assays that can be validated with clinical insights about their utility at the point of care," said Dr. Christopher Yoo, CEO of MedTrust.  "The result of this joint effort will be better decisions based on the most accurate molecular knowledge available about an individual patient's disease.  We believe Avantra's technology will bring a higher level of accuracy than what's currently available and MedTrust is delighted to work with Avantra on this important advancement in cancer care."

About Avantra Biosciences Corporation

Avantra Biosciences is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis. Initially focused on oncology, Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site. For more information visit:

About MedTrust Online, LLC

MedTrust Online LLC,, headquartered in Scottsdale, Arizona, provides oncologists with clinically useful technology applications and solutions. MedTrust Online brings together experts in oncology, information technology, computational biology, pharmaceutical drug development, and personalized medicine to capture, organize, analyze, integrate and present the most up-to-date medical facts from a vast array of sources. This data is provided to doctors in a comprehensive yet concise way unavailable anywhere else.

SOURCE Avantra Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... The hospitals ... to several aspects of orthopedic care. They have received recognition for excellence from ... orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based on ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for ... with some of the staff members at their recovery center. The videos highlight some ... as some of the things that make their recovery program so unique. , “Making ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... award at Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, ... Chiropractor and University President Carl S. Cleveland III on October 16. , “Katie ...
Breaking Medicine News(10 mins):